AstraZeneca to Resume Enrolment for New Cancer Drug Trial
November 22 2016 - 2:53AM
Dow Jones News
By Tapan Panchal
LONDON--AstraZeneca PLC (AZN.LN) said Tuesday the U.S. Food and
Drug Administration had lifted its partial ban on head and neck
cancer treatment drug trials, and the company had consequently
resumed new patient enrolment for the trials.
The pharmaceutical company said the regulator lifted its partial
hold on the enrolment of new patients with head and neck squamous
cell carcinoma for clinical trials of durvalumab as monotherapy and
in combination with tremelimumab or other potential medicines.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
November 22, 2016 02:38 ET (07:38 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
